Minjuvi or Monjuvi Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Minjuvi or Monjuvi market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to a growing emphasis on combination drug approvals, the expansion of access programs, reimbursement policies favorable to targeted therapies, the high mortality rate associated with untreated relapsed DLBCL, and the increasing demand for biologics in oncology.

Growth during the market's forecast period can be attributed to a focus on elderly patient populations, rising healthcare awareness, increased use of CD19-targeted therapies, government and NGO funding for cancer research, and an increase in cancer survivorship rates. Major trends during the forecast period include innovations in monoclonal antibodies, orphan drug designation, a shift from chemotherapy to immunotherapy, the integration of artificial intelligence in oncology drug discovery, and the introduction of biosimilars.

The rise in cancer prevalence is expected to drive the growth of the minjuvi or monjuvi market in the future. Cancer refers to a group of diseases marked by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer can be attributed to factors such as aging, lifestyle choices such as smoking and poor diet, environmental exposures, genetic factors, and advancements in detection methods. Minjuvi (Monjuvi), when used in combination with lenalidomide, is employed to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL), providing enhanced treatment options by effectively targeting cancer cells. For example, in August 2024, the Australian Institute of Health and Welfare, an Australian national agency for health and welfare statistics, projected that by 2034, approximately 209,000 new cancer diagnoses would be made in Australia, a significant rise from the estimated 169,000 cases expected in 2024. Additionally, cancer is expected to account for about 3 out of every 10 deaths in the country in 2024. Therefore, the increasing prevalence of cancer is fueling the growth of the minjuvi or monjuvi market.

A key trend in the minjuvi or monjuvi market is the development of innovative therapies, such as combination therapy, to improve treatment effectiveness and outcomes for patients with B-cell malignancies, particularly those with relapsed or refractory DLBCL. Combination therapy involves using two or more treatments, such as medications or therapies, together to treat a medical condition. This approach aims to boost the overall effectiveness of treatment, often by targeting different mechanisms or pathways involved in the disease. For instance, in February 2024, Knight Therapeutics Inc., a Canada-based pharmaceutical company, launched Minjuvi (tafasitamab) in Brazil through its affiliate, United Medical Ltda. In combination with lenalidomide, Minjuvi (tafasitamab) is an immunotherapy treatment for relapsed or refractory DLBCL patients who are not eligible for autologous stem cell transplantation. This combination has demonstrated a significant objective response rate and is recommended as a preferred second-line treatment according to NCCN guidelines.

In February 2024, Incyte Corporation, a US-based pharmaceutical company, acquired full rights to Monjuvi from MorphoSys AG for $25 million. This acquisition aims to grant Incyte complete control over Monjuvi's global commercialization and clinical development, improving operational efficiencies and driving cost synergies. This strategic move enables Incyte to capitalize on the drug’s potential to expand its lymphoma treatment indications. MorphoSys AG, a Germany-based biotech company, specializes in providing monjuvi.

The key company operating in the minjuvi or monjuvi market is Incyte Corporation.

North America was the largest region in the minjuvi or monjuvi market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in minjuvi or monjuvi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the minjuvi or monjuvi market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Minjuvi (tafasitamab) is a monoclonal antibody used for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It works by targeting and binding to CD19 on malignant B cells, which activates immune system-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC) and apoptosis. This mechanism helps reduce tumor burden by eliminating cancerous B cells while leaving normal ones unharmed.

The primary indications for minjuvi or monjuvi are relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other conditions. Relapsed or refractory DLBCL refers to cases where the lymphoma returns after treatment or fails to respond to initial therapy. The formulations are available as intravenous infusions and pre-filled syringes, with distribution channels including hospitals, oncology clinics, specialty pharmacies, and home healthcare services. It is used by various patient groups, including adult and geriatric patients.

The minjuvi or monjuvi market research report is one of a series of new reports that provides minjuvi or monjuvi market statistics, including minjuvi or monjuvi industry global market size, regional shares, competitors with a minjuvi or monjuvi market share, detailed minjuvi or monjuvi market segments, market trends and opportunities, and any further data you may need to thrive in the minjuvi or monjuvi industry. This minjuvi or monjuvi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The minjuvi or monjuvi market consists of sales of monoclonal antibody therapies, combination therapies, and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.